Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma.

Patrick Schöffski Rastislav Bahleda Andrew J Wagner Melissa A Burgess Niels Junker Michael Chisamore Patrick Peterson Anna M Szpurka Matteo Ceccarelli William D Tap

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Antitumor activity was observed in some patients in DEC, combination was well tolerated with manageable safety profile. Further studies are warranted to evaluate efficacy/mechanistic impact of platelet-derived growth factor receptors inhibitor with immune checkpoint modulator coadministration.

Keyphrases

growth factor
locally advanced
squamous cell carcinoma
end stage renal disease
newly diagnosed
chronic kidney disease
rectal cancer
neoadjuvant chemotherapy
prognostic factors
peritoneal dialysis
radiation therapy
advanced non small cell lung cancer
lymph node
liver metastases
tyrosine kinase
case control